Pembrolizumab: tested on its own

368 studies: no other medicine in its arm. Page 2 of 4. Open to participants first (59), then studies with results posted, then the rest; newest registration first within each.

Adjuvant Pembrolizumab for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma at High Risk of RecurrenceCompletedNCT03322267Phase 2Results posted Report a problem
Pembrolizumab in Treating Patients With Bladder Cancer Undergoing Radical CystectomyCompletedNCT03319745Phase 2Results posted Report a problem
Study of Pembrolizumab and Radiotherapy in Liver CancerTerminatedNCT03316872Phase 2Results posted Report a problem
Pembrolizumab in Neoplasms or LymphomasSuspendedNCT03316573Phase 2Results posted Report a problem
Sequencing of Stereotactic Ablative Body Radiotherapy in Combination With PD-1 Blockade Using Pembrolizumab in Metastatic Non-Small Cell Lung CarcinomaTerminatedNCT03307759Phase 1Results posted Report a problem
Pembrolizumab in Elderly Patients With Advanced Lung CancerCompletedNCT03293680Phase 2Results posted Report a problem
Anti-PD(L)1 and SBRT in the Treatment of Advanced, Platinum-Refractory Urothelial CarcinomaTerminatedNCT03287050Phase 2Results posted Report a problem
Augmentation of the Graft vs. Leukemia Effect Via Checkpoint Blockade With PembrolizumabTerminatedNCT03286114Phase 1Results posted Report a problem
Study of Pembrolizumab (MK-3475) in Adults With Recurrent/Metastatic Cutaneous Squamous Cell Carcinoma (cSCC) or Locally Advanced Unresectable cSCC (MK-3475-629/KEYNOTE-629)CompletedNCT03284424Phase 2Results posted Report a problem
Phase II Trial of Pembrolizumab in Recurrent or Residual High Grade MeningiomaActive, not recruitingNCT03279692Phase 2Results posted Report a problem
Pembrolizumab Activity in Patients With Homologous Recombination Competent and Deficient TumorsCompletedNCT03274661Phase 2Results posted Report a problem
Pembrolizumab and Radiation Therapy in Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT03267888Phase 1/2Results posted Report a problem
Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL), and Other Extranodal Diffuse Large B-cell LymphomasCompletedNCT03255018Phase 2Results posted Report a problem
PD-1 Inhibition to Determine CNS Reservoir of HIV-InfectionCompletedNCT03239899Phase 1Results posted Report a problem
Focused Ultrasound and Pembrolizumab in Metastatic Breast CancerTerminatedNCT03237572Phase 1Results posted Report a problem
Pembrolizumab and External Beam Radiation Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin LymphomaCompletedNCT03210662Phase 2Results posted Report a problem
Neoadjuvant Anti PD-1 Immunotherapy in Resectable Non-small Cell Lung CancerCompletedNCT03197467Phase 2Results posted Report a problem
Effect of Pembrolizumab (Keytruda®) on Biomarkers in Early Breast Cancer.CompletedNCT03197389Early Phase 1Results posted Report a problem
Pembrolizumab for the Treatment of Recurrent High Grade Neuroendocrine CarcinomaTerminatedNCT03190213Phase 2Results posted Report a problem
Pembrolizumab and Involved Site Radiation Therapy for Early Stage Relapsed or Primary Refractory Hodgkin LymphomaActive, not recruitingNCT03179917Phase 2Results posted Report a problem
Pembrolizumab in Intermediate Risk Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)TerminatedNCT03167151Phase 1/2Results posted Report a problem
Pembrolizumab in Advanced Hepatocellular Carcinoma as Second-line Treatment After Failure of SorafenibCompletedNCT03163992Phase 2Results posted Report a problem
A Study of Pembrolizumab And Platinum With Radiotherapy in Cervix CancerTerminatedNCT03144466Phase 1Results posted Report a problem
Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564)CompletedNCT03142334Phase 3Results posted Report a problem
Pembrolizumab in Patients With Leptomeningeal DiseaseTerminatedNCT03091478Phase 2Results posted Report a problem
Trial of Consolidation Pembrolizumab After Concurrent Chemotherapy and Proton Reirradiation for Thoracic Recurrences of Non-Small Cell Lung CancerCompletedNCT03087760Phase 2Results posted Report a problem
Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic CarcinomaCompletedNCT03087019Phase 2Results posted Report a problem
Phase II Trial of Continuation Therapy in Advanced NSCLCCompletedNCT03083808Phase 2Results posted Report a problem
Pembrolizumab in Recurrent or Metastatic Medullary Thyroid CancerCompletedNCT03072160Phase 2Results posted Report a problem
PD-1 Inhibition in Advanced Myeloproliferative NeoplasmsCompletedNCT03065400Phase 2Results posted Report a problem
Pembrolizumab, Radiotherapy, and Chemotherapy in Neoadjuvant Treatment of Malignant Esophago-gastric Diseases (PROCEED)CompletedNCT03064490Phase 2Results posted Report a problem
Study of Pembrolizumab (MK-3475) or Placebo Given With Best Supportive Care in Asian Participants With Previously Treated Advanced Hepatocellular Carcinoma (MK-3475-394/KEYNOTE-394)CompletedNCT03062358Phase 3Results posted Report a problem
The Addition of Pembrolizumab to Postoperative Radiotherapy in Cutaneous Squamous Cell Cancer of the Head and NeckCompletedNCT03057613Phase 2Results posted Report a problem
Phase II PEMBROLIZUMAB + PALLIATIVE RADIOTHERAPY IN BCTerminatedNCT03051672Phase 2Results posted Report a problem
Efficacy and Safety Study of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian Participants With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-line Therapy With Platinum and Fluoropyrimidine (MK-3475-063/KEYNOTE-063)TerminatedNCT03019588Phase 3Results posted Report a problem
A Trial of Pembrolizumab for Refractory Atypical and Anaplastic MeningiomaTerminatedNCT03016091Phase 2Results posted Report a problem
PembROlizuMab Immunotherapy Versus Standard Chemotherapy for Advanced prE-treated Malignant Pleural MesotheliomaCompletedNCT02991482Phase 3Results posted Report a problem
HDCRT Plus Pembrolizumab in Advanced MalignanciesCompletedNCT02987166Phase 1Results posted Report a problem
Pilot Study of Pembrolizumab Treatment for Disease Relapse After Allogeneic Stem Cell TransplantationCompletedNCT02981914Early Phase 1Results posted Report a problem
Pembrolizumab in Refractory Advanced Esophageal CancerCompletedNCT02971956Phase 2Results posted Report a problem
Pembrolizumab in Treating Patients With Hormone Receptor Positive, Localized Inflammatory Breast Cancer Who Are Receiving Hormone Therapy and Did Not Achieve a Pathological Complete Response to ChemotherapyActive, not recruitingNCT02971748Phase 2Results posted Report a problem
Pembrolizumab in Patients With Locally Advanced or Metastatic Skin CancerCompletedNCT02964559Phase 2Results posted Report a problem
Pembrolizumab After Radiation Therapy in Treating Patients With Pleural Malignant MesotheliomaCompletedNCT02959463Phase 1Results posted Report a problem
Pembrolizumab in Treating Patients With Small Bowel Adenocarcinoma That is Metastatic or Locally Advanced and Cannot Be Removed by SurgeryActive, not recruitingNCT02949219Phase 2Results posted Report a problem
A Study of Pembrolizumab in Patients With Neuroendocrine TumorsCompletedNCT02939651Phase 2Results posted Report a problem
Pembrolizumab in Metastatic Anal CancerCompletedNCT02919969Phase 2Results posted Report a problem
Pembrolizumab in Ultramutated and Hypermutated Endometrial CancerCompletedNCT02899793Phase 2Results posted Report a problem
Pembrolizumab in HNSCC With Residual Disease After RadiationTerminatedNCT02892201Phase 2Results posted Report a problem
Pembrolizumab In Central Nervous System MetastasesActive, not recruitingNCT02886585Phase 2Results posted Report a problem
Pembrolizumab in Treating Patients With High Risk Oral Intraepithelial NeoplasiaCompletedNCT02882282Phase 2Results posted Report a problem
Pembrolizumab in Treating Patients With EGFR Mutant, Tyrosine Kinase Inhibitor Naive Advanced Non-Small Cell Lung CancerCompletedNCT02879994Phase 2Results posted Report a problem
Pembrolizumab in Advanced/Metastatic Acral Lentiginous MelanomaCompletedNCT02875132Phase 2Results posted Report a problem
Study of Pembrolizumab Versus Docetaxel in Participants Previously Treated for Non-Small Cell Lung Cancer (MK-3475-033/KEYNOTE-033)CompletedNCT02864394Phase 3Results posted Report a problem
Stereotactic Radiotherapy and Anti-PD1 Antibody (Pembrolizumab) for Oligometastatic Renal TumoursCompletedNCT02855203Phase 1/2Results posted Report a problem
Study of Pembrolizumab (MK-3475) Monotherapy in Locally Advanced/Metastatic Renal Cell Carcinoma (MK-3475-427/KEYNOTE-427)CompletedNCT02853344Phase 2Results posted Report a problem
A Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), In Patients With Surgically Accessible Recurrent/Progressive GlioblastomaActive, not recruitingNCT02852655Phase 1Results posted Report a problem
Preoperative Chemoradiotherapy and MK-3475 for Esophageal Squamous Cell Carcinoma (ACTS-29)CompletedNCT02844075Phase 2Results posted Report a problem
A Randomized, Double-Blind Phase II Study of Adjuvant Pembrolizumab Versus Placebo in Head and Neck Cancers at High Risk for Recurrence- the PATHWay StudyCompletedNCT02841748Phase 2Results posted Report a problem
PI Pembro in Combination With Stereotactic Body Radiotherapy for Liver Metastatic Colorectal CancerCompletedNCT02837263Phase 1Results posted Report a problem
Trial of Pembrolizumab for Advanced Penile Squamous Cell CarcinomaTerminatedNCT02837042Phase 2Results posted Report a problem
Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Pembrolizumab (MK-3475) in Chinese Participants With Non-Small-Cell Lung Cancer (MK-3475-032/KEYNOTE-032)CompletedNCT02835690Phase 1Results posted Report a problem
Pembrolizumab and Palliative Radiation Therapy in Treating Patients With Metastatic Esophagus, Stomach, or Gastroesophageal Junction CancerCompletedNCT02830594Phase 2Results posted Report a problem
Safety and Efficacy Study of Pembrolizumab (MK-3475) in Chinese Participants With Locally Advanced or Metastatic Melanoma (MK-3475-151/KEYNOTE-151)CompletedNCT02821000Phase 1Results posted Report a problem
Neoadjuvant PembrolizumabCompletedNCT02818920Phase 2Results posted Report a problem
Study of Pembrolizumab (MK-3475) in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)(MK-3475-199/KEYNOTE-199)CompletedNCT02787005Phase 2Results posted Report a problem
Pembrolizumab in Treating Patients With Desmoplastic Melanoma That Can or Cannot Be Removed by SurgeryActive, not recruitingNCT02775851Phase 2Results posted Report a problem
High Dose Cytarabine Followed by Pembrolizumab in Relapsed/Refractory AMLCompletedNCT02768792Phase 2Results posted Report a problem
Pembrolizumab in Treating Minimal Residual Disease in Patients With Acute Lymphoblastic LeukemiaTerminatedNCT02767934Phase 2Results posted Report a problem
Pembrolizumab in Patients With Non-Small Cell Lung Cancer and a Performance Status 2CompletedNCT02733159Phase 2Results posted Report a problem
Study to Assess the Efficacy of Pembrolizumab Plus Radiotherapy in Metastatic Triple Negative Breast Cancer PatientsCompletedNCT02730130Phase 2Results posted Report a problem
A Study of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic CancersCompletedNCT02728830Early Phase 1Results posted Report a problem
Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are MetastaticActive, not recruitingNCT02721732Phase 2Results posted Report a problem
A Phase II Study of Pembrolizumab as Post-Remission Treatment of Patients ≥ 60 With AMLCompletedNCT02708641Phase 2Results posted Report a problem
Switch Maintenance Pembrolizumab in Patients With NSCLC After First Line Platinum Doublet ChemotherapyCompletedNCT02705820Phase 2Results posted Report a problem
SBRT Plus Pembrolizumab and Trametinib for Pancreatic CancerCompletedNCT02704156Phase 2Results posted Report a problem
Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Advanced Hepatocellular Carcinoma (MK-3475-224/KEYNOTE-224)CompletedNCT02702414Phase 2Results posted Report a problem
Study of Pembrolizumab (MK-3475) vs. Best Supportive Care in Participants With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-240/KEYNOTE-240)CompletedNCT02702401Phase 3Results posted Report a problem
Pembrolizumab in Anaplastic/Undifferentiated Thyroid CancerCompletedNCT02688608Phase 2Results posted Report a problem
Phase II Trial of Sequential Consolidation With Pembrolizumab Followed by Nab-paclitaxelCompletedNCT02684461Phase 2Results posted Report a problem
Efficacy and Safety Study of Pembrolizumab (MK-3475) in Participants With Advanced Recurrent Ovarian Cancer (MK-3475-100/KEYNOTE-100)CompletedNCT02674061Phase 2Results posted Report a problem
Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical CarcinomaActive, not recruitingNCT02673333Phase 2Results posted Report a problem
Pembrolizumab Alone or Sequentially Following Single Fraction Non-ablative Radiation to One of the Target Lesions, in Previously Treated Patients With Stage IV NSCLCCompletedNCT02658097Phase 2Results posted Report a problem
Pembrolizumab (Keytruda) in Advanced Hepatocellular CarcinomaCompletedNCT02658019Phase 2Results posted Report a problem
Pembrolizumab in Patients Failing to Respond to or Relapsing After CAR T Cell Therapy for Relapsed or Refractory LymphomasCompletedNCT02650999Phase 1/2Results posted Report a problem
Pembrolizumab With Locally Delivered Radiation Therapy for the Treatment of Metastatic Esophageal CancersCompletedNCT02642809Phase 1Results posted Report a problem
Pembrolizumab for HPV-associated Recurrent Respiratory Papilloma PatientsCompletedNCT02632344Phase 2Results posted Report a problem
Study of Pembrolizumab (MK-3475) in Platinum Pre-treated Recurrent/Metastatic Nasopharyngeal Cancer (MK-3475-122/KEYNOTE-122)CompletedNCT02611960Phase 3Results posted Report a problem
Pembrolizumab + Radiation for Locally Adv SCC of the Head and Neck (SCCHN) Not Eligible CisplatinCompletedNCT02609503Phase 2Results posted Report a problem
Pembrolizumab in Treating Patients With Intermediate or High-Risk Smoldering Multiple MyelomaActive, not recruitingNCT02603887Early Phase 1Results posted Report a problem
Study of Pembrolizumab in Subjects With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-Line Therapy With Platinum and Fluoropyrimidine: Integration of Molecular Subtypes Through Integrative Genomic AnalysisCompletedNCT02589496Phase 2Results posted Report a problem
Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma or Relapsed or Refractory Richter Syndrome (MK-3475-170/KEYNOTE-170)CompletedNCT02576990Phase 2Results posted Report a problem
Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/ Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)CompletedNCT02564263Phase 3Results posted Report a problem
Study of Pembrolizumab (MK-3475) in Previously-Treated Participants With Advanced Carcinoma of the Esophagus or Esophagogastric Junction (MK-3475-180/KEYNOTE-180)CompletedNCT02559687Phase 2Results posted Report a problem
Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119)CompletedNCT02555657Phase 3Results posted Report a problem
Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by SurgeryActive, not recruitingNCT02506153Phase 3Results posted Report a problem
Study of Pembrolizumab (MK-3475) vs Placebo for Participants With Non-small Cell Lung Cancer After Resection With or Without Standard Adjuvant Therapy (MK-3475-091/KEYNOTE-091)CompletedNCT02504372Phase 3Results posted Report a problem
Testing the PD-1 Inhibitor Pembrolizumab as Maintenance Therapy After Initial Chemotherapy in Metastatic Bladder CancerCompletedNCT02500121Phase 2Results posted Report a problem
Pembrolizumab in Subjects With Incurable Platinum-Refractory Germ Cell TumorsTerminatedNCT02499952Phase 2Results posted Report a problem
Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Previously-Treated Locally Advanced Unresectable or Metastatic Colorectal Cancer (MK-3475-164/KEYNOTE-164)CompletedNCT02460198Phase 2Results posted Report a problem
Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-087/KEYNOTE-087)CompletedNCT02453594Phase 2Results posted Report a problem

← Pembrolizumab